The hexose galactose is almost exclusively metabolized in the liver, a property that is utilized in the galactose elimination capacity test, GEC (47, 48) . The GEC estimates the liver's maximal capacity for removing and metabolizing blood-borne galactose and this reflects how well the individual liver functions. The clinical value of the GEC as a prognostic marker in patients with liver disease is well-documented (15, 16, 20, 34, 35, 41, 43) . Galactose kinetics and metabolism are therefore of great interest for hepatologists and have been studied thoroughly. Studies have shown that galactose enters hepatocytes freely from the blood (11) and that the first step in intracellular metabolism of galactose is phosphorylation to galactose-1-phosphate (17) , a reaction catalyzed by the galactokinase enzyme. This phosphorylation has furthermore been shown to be the rate limiting step in hepatic metabolism of galactose and follows Michaelis-Menten saturation kinetics in vivo (22, 29) . The GEC test thus reflects the total in vivo activity of the galactokinase enzyme.
Previous studies of galactose metabolism have been carried out in purified enzymes (2, 3, 46, 49) , isolated perfused rat livers (24, 25, 44) , dog livers (11) , isolated perfused pig livers (22, 23, 28) , anaesthetized pigs (26, 51) , and in human subjects (47, 48, 27, 32, 42) . So far, all in vivo studies have been based on measurements of galactose concentrations in arterial blood and in some cases supplemented with liver vein blood samples. Such studies yield information on the net uptake of galactose across the whole liver but not of specific rate constants for hepatic uptake and metabolism of galactose. Advanced PET technology has now made this feasible (45) . The galactose analog 2-deoxy-galactose has been labeled with 18 F forming 2- 19 ). External detection by PET of the time-dependent distribution of FDGal in tissue following an IV injection makes it possible to estimate specific rate constants for hepatic uptake and metabolism in vivo (45) . No such PET studies of FDGal kinetics in the liver have yet been published although PET studies of rodents have shown that radioactivity following an IV infusion of FDGal accumulates very specifically in the liver (9, 12, 19) . The liver's special dual blood supply from the hepatic artery (HA) and the portal vein (PV) has been the main obstacle for more detailed studies (9) .
The special arrangement of the liver between the portal vein drained viscera and the systemic blood circulation makes it difficult to calculate the correct flow-weighted dual input, viz. the mixed arterial-portal input. Since portal vein catheterization is not possible in humans, animals are suitable for such studies. In the recent years this have been utilized in studies of other tracer kinetics such as the sugar analog 2- (18, 36) . These studies have shown that the hepatic net metabolic clearance of FDG during quasi-steady state metabolism can be calculated using linear representation of dynamic PET data and the single arterial input (18, 36) .
The aim of the present in vivo PET study in pigs was to evaluate the feasibility of using FDGal as a PET tracer in studies of hepatic galactose metabolism and to gain new insight into galactose kinetics. We used the anaesthetized pig model which has the advantage that blood sampling from the portal vein is possible. This gives us the opportunity to determine the mixed arterial-portal input i.e. the dual input.
Furthermore, the metabolism of the pig liver resembles that of the human liver very closely. Our set-up allowed us to estimate specific kinetic parameters for transport 6 from blood to hepatocyte and the subsequent intracellular metabolism of FDGal. We also studied the importance of using the liver's dual input in the estimation of the net metabolic clearance of FDGal versus using the single arterial input. If the net metabolic clearance of galactose can be quantified using dynamic FDGal PET and the single arterial input this makes the method applicable for human studies.
Materials and Methods
Study design. The left femoral artery and vein were exposed and Avanti catheters (Cordis Corporation, USA) inserted into both vessels. After checking interdigital reflexes to secure sufficiently deep anesthesia, 4 mg pancoronium was injected IV. The abdomen was opened through a 30 cm long subcostal incision below the right curvature and the hepatoduodenal ligament identified. The common bile duct, the hepatic artery (HA) and the portal vein (PV) were exposed and ultrasound transittime flow-meters (CardioMed; In vivo Aps., Denmark) placed around the two blood vessels for flow measurements. A 5.3 F polyethylene catheter (William Cook Europe, Denmark) was inserted into the PV for blood sampling. It was placed downstream to the flow-meter in order not to disturb flow measurements. Finally, the surgical incision was closed and catheters and lines of the flow-meters were secured to the abdominal surface to avoid displacement.
Six of the pigs received an intravenous injection of 70 mmol galactose (Kabi, Sweden) in 50 mL isotonic saline (0.9 % NaCl) followed by a constant IV infusion of a galactose solution with concentrations ranging from 139 to 348 µmol galactose/L isotonic saline (infusion rate was 216 mL pr hour). The infusion was started 75 to 90 minutes prior to the PET study in order to allow for the galactose to distribute and reach a steady-state concentration in blood. The infusion was sustained throughout the study. Four pigs received an IV bolus of isotonic saline followed by a constant infusion of isotonic saline without galactose.
PET recordings and blood sampling. After abdominal surgery, the anaesthetized pig was placed in a supine position with the liver within the 15 cm field of view of the PET camera (Siemens ECAT EXACT HR-47, CTI/Siemens Medical Systems, Inc., Knoxville, USA). A five minutes scan using a rotating external 68 GE/
68
GA rod was performed to ensure that the liver was in the center of the camera's field of view.
After any necessary adjustments, a transmission scan of 15 minutes was performed for later attenuation correction of the emission recordings.
Two dynamic CO recordings were performed in each animal after inhalation of 1000 MBq CO administered through the respirator to determine the vascular volume of the liver (36) . Dual estimates from each pig deviated less than five per cent from each other and the individual mean value of the two estimates were accordingly used.
Ten minutes after the last CO recording we injected 200 MBq FDGal in 10 mL saline through the catheter in the femoral vein during the initial 15 seconds of the dynamic PET recording. The FDGal-protocol consisted of 52 time frames (18x5s, 15x10s, 4x30s, 4x60s, 6x300s, and 5x600s; total 90 minutes). FDGal was produced at the PET center's own radiochemistry laboratory according to the method described elsewhere (5).
Emission data were corrected for radioactive decay back to start of the scan. All recordings were reconstructed in a Gaussian filtered back projection mode with an During the FDGal PET recording, successive blood samples (0.5 mL) were drawn from the femoral artery and the portal vein at 18x5s, 6x10s, 3x20 s, 3x60 s, 1x120 s, 1x240 s, 1x360 s, and 7x600 s. Blood concentrations of radioactivity were measured using a well counter (Packard Instruments Co., Meriden, CT), corrected for radioactive decay back to start of the scan and blood concentrations of radioactivity over time (time-activity-curves, TACs) for portal venous and arterial blood were generated. In order not to disturb the flow in the hepatic artery during the study we withdrew arterial blood samples from the femoral artery, since the concentration of FDGal in the femoral artery is equal to that in the hepatic artery without any detectable time-delay.
The arterial blood concentration of galactose was determined enzymatically (31) three times during the FDGal PET recording.
Blood flow rates in the PV and the HA were recorded by the transit-time flow-meters every 10 seconds during the initial three minutes of the PET-recording, then every 30 seconds for the next two minutes, at five and 10 minutes, and then every 10 minutes for the rest of the study period.
Arterial blood pressure values were monitored every 30 minutes throughout the Plasma proteins were precipitated by adding 0.5 mL plasma to 0.5 mL acetonitrile.
After centrifugation for 5 minutes at 13.000 rpm (IEC Micromax-centrifuge, Metric A/S, Taastrup, Denmark), the acetonitrile was evaporated in vacuum. The supernatant was centrifuged again for 2 min at 13,000 rpm and the subsequent supernatant divided in to two fractions (A and B).
Fraction A was analyzed applying a system previously described for the analysis of the content of metabolites formed from the sugar analog 2-[ Based on aliquot, the recovery from radio-HPLC was higher than 90% both for fractions A and B.
Data Analysis
Regions of interest (ROIs) were drawn in the liver using an image of the mean FDGal radioactivity concentrations from 10 to 90 minutes, carefully excluding large vessels by viewing the image side-by-side with the corresponding CO images (Ecat7 Software). The ROIs were summed into a volume of interest (VOI) which was transferred to the dynamic scan and a tissue time-activity curve (TAC) of the time course of the tissue concentration of radioactivity in that region was extracted.
The flow-weighted dual-input concentration was calculated as:
where F(t) HA and F(t) PV are the flow rates in HA and PV, respectively, and c(t) HA and c(t) PV the radioactivity concentrations in the corresponding vessels at a given time, t.
The hepatic blood perfusion, Q (mL blood/min/mL liver tissue) was calculated as total flow (from the ultrasound transit-time flow-meters) divided by the wet liver weight and corrected for tissue density (1.07 g/mL; M. Sørensen, unpublished observation).
Whole blood concentrations of galactose and FDGal were used because no quantitatively important amount of galactose enters pig erythrocytes (22) . The estimated clearances are hence in terms of per mL whole blood.
FDGal kinetics from non-linear regression analysis. (Table 1) .
Steady-state metabolic clearance of FDGal from linear representation of data. Linear
representation of data is used to yield a robust measure of the net metabolic clearance of tracer. In this representation, (M 1 )(t)/c i (t) is plotted against (t) as (10, 39):
where 32 12 Extraction fractions. The extraction fraction, E, is related to the clearance and perfusion as:
where K is the clearance (mL blood/min/mL tissue) and Q is the perfusion. Inserting the initial unidirectional clearance, K 21 , in Eq. 4 gives the initial extraction fraction, 
which is applicable in the sinusoidal perfusion model and at approx. first-order kinetics (exps. 1 -4) (22, 29) .
The analog-effect. Six of the animals had a constant infusion of galactose which was 
At high concentration of galactose, c Gal , the net metabolic clearance, K FDGal , in Eqs. The kinetics of FDGal is always first-order due to low dose injected.
Results
Arterial blood concentrations of galactose (c Gal ) ranged from <0.01 to 6.65 mmol/L (Table 1) . As mentioned, the reaction catalyzed by galactokinase is at nearsaturation when c Gal > 3 mmol/L (exps. 7 -10). FDGal kinetics from non-linear regression analysis. Fig. 3 shows examples of fitting the model in Fig. 1 to data by non-linear regression. We initially compared the goodness of the fit using a kinetic model without a k 23 
Discussion
The present study is the first in vivo PET study with estimation of kinetic parameters of galactose uptake and metabolism in pig liver using the galactose analog FDGal.
The results have provided new insights into the dynamic behavior of galactose in the intact liver. Since galactose is not normally present in blood during fasting we were able to study the effect of a constant infusion of non-radioactive (cold) galactose on the FDGal kinetics. FDGal followed first-order kinetics due to the low amount injected (tracer dose). Near-saturation of the enzymatic system by non-radioactive galactose caused a strong competition between galactose and FDGal for the galactokinase, which affected the kinetics of FDGal significantly. This is illustrated in Figure 3 and in Table 1 which shows the dramatic effect of galactose on the hepatic accumulation of first-order kinetics of galactose due to the high enzymatic removal of FDGal.
As a consequence of a very high permeability of the hepatocyte plasma membrane for both galactose and FDGal, we were unable to estimate the true rate constant for the unidirectional clearance, K 21 . It was equal to or even higher than the blood perfusion Q, and since the operational rate constant cannot exceed the perfusion we set K 21 equal to Q. As a result of this, the initial extraction fraction, E 0 , was unity in all experiments. This demonstrates a very high capacity of the hepatocyte membrane for transport of galactose from sinusoid to hepatocyte in agreement with the findings in dog livers by Goresky who used the multiple indicator dilution method (11 FDGal are both phosphorylated by the galactokinase enzyme ( Fig. 5 and Table 1 ).
PET studies in rodents also found that galactose caused a decrease in hepatic accumulation of FDGal, but the kinetics of the underlying processes was not studied (9, 12, 19) .
The distinct difference between the initial time course of blood TACs for arterial and the flow-weighted dual input (Fig. 3) demonstrates why the single arterial input cannot be used to estimate specific kinetic parameters for hepatic uptake and removal rates which are sensitive to the changes in the initial data (36) . There was no statistically significant difference between the quasi steady-state parameters (4), with further conversion of FDGal-1-P into metabolites that might escape the hepatocytes. This escape of FDGal-metabolites would be very slow and result in very low concentrations in peripheral blood to explain why we did not detect any FDGal-metabolites in the blood samples. Another explanation could be that there actually might be galactose-1-phosphatase in the hepatocytes. Some enzymes have indeed been shown to be able to de-phosphorylate galactose-1-phosphate (13, 38) , but these enzymes have yet not been isolated from liver tissue. If present, it would take some time before enough FDGal-1-P is formed and hence substrate is available to the enzymes, similar to the delay hypothesis of the de- phosphorylation of FDG-6-phosphate in brain (14) . The enzymes might even be located in the intracellular compartments that are not easily accessible for the FDGal-1-P (such as the endoplasmatic reticulum) which would cause a further time delay (8) . Consequently, the k 23 is not showing its effect on the data until after some time.
In support of this, when we fitted a 4k-model to our data up to 40 minutes after injection the analysis yielded k 23 for FDGal. However, the galactokinase enzyme has a much greater affinity for galactose than for FDGal which in Eq. 8b is expressed in terms of the ratio between the two intrinsic clearances of the two substances. A ratio of 6.92 is quite high compared to the LC for FDG in pig liver, which in a recent study was estimated to be close to unity (18) . The hepatic uptake of glucose is strictly regulated by factors such as insulin, however, which caused the LC to vary from 0.98 during hyperinsulinemia to 1.18 during fasting (18) . Hepatic removal of galactose is not affected by insulin or glucose levels in blood (44) and neither is the uptake of FDGal (9) and can therefore be assumed to be unaffected by such factors. Furthermore, since is the ratio between the two intrinsic clearances of the FDGal and galactose, it is not concentration-dependent.
The importance of including in FDGal PET studies depends on the purpose of the studies. If one is interested in following the same patient over time, one could just calculate the maximal hepatic removal rate of FDGal, as discussed for FDG (30) . If, however, the true metabolism of galactose is wanted, then the correct LC is important to know. With loss of functional liver mass, the total V max of galactokinase is reduced for both galactose and FDGal. This would probably not affect since it is merely the ratio between the two intrinsic clearances.
The traditional galactose elimination capacity test, GEC, as developed by Tygstrup (47, 48) , gives a good estimate of the whole liver's GEC. The test is however biased by a small but varying extra-hepatic galactose metabolism. Compared to this, the novel FDGal PET method presented in this study is not biased by any extra-hepatic metabolism of galactose since it is based on 3 dimensional imaging of the liver's galactose uptake. The PET method also makes it possible to explore if there are regional differences in the hepatic GEC in patients with for example cirrhosis of the liver or primary liver tumors. In the present study of healthy pig livers there was no statistically significant regional variation and since there are no good pig models for chronic hepatic pathophysiological conditions we were unable to include such studies.
Conclusion
By using advanced PET technology we were able to study specific rate constants for , was calculated from Eq. 8a, which is only applicable in cases with near-saturation kinetics, viz. exps. 7 -10. In these cases the kinetics approximated saturation with 94 -97 %.
